ReShape Lifesciences Inc. has entered into a promissory note agreement with Vyome Therapeutics, Inc., as disclosed in a recent Form 8-K filing. Under this agreement, ReShape will provide a loan of $200,000 to Vyome, intended for working capital and expenses related to their merger agreement dated July 8, 2024. The loan will bear an interest rate of 8% per annum and is due for repayment by September 30, 2025, unless the merger is completed beforehand. If the merger proceeds as planned, Vyome will not have to repay the loan, with the outstanding amount counted as ReShape's net cash under the merger terms. If the merger agreement is terminated under specific conditions, the promissory note will become a senior secured obligation for Vyome.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。